SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it gained FDA market authorization for its Common Hereditary Cancers Panel. This ...
Invitae Corporation faces significant challenges in addressing its liquidity concerns. Invitae has entered into an Asset Purchase Agreement with Natera, involving the sale of specific assets in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback